Systems of Risk Stratification of Malignancy by Ultrasound of Thyroid Nodules

Luis Antonio Rodriguez Arrieta 1, Alejandro Roman-Gonzalez 2, Carlos A. Builes Barrera 2

1. Endocrinology, University of Antioquia, Medellin, COL. 2. Endocrinology, University of Antioquia, Hospital San Vicente Foundation, Medellin, COL.

Corresponding author: Luis Antonio Rodriguez Arrieta, luis.rodrigueza1@udea.edu.co

Abstract

Thyroid nodules (TN) are more frequently identified with the use of thyroid ultrasonography, and they have a low risk of malignancy. Ultrasonographic features have been established that increase the probability of being faced with thyroid carcinoma; however, individually, these characteristics do not perform adequately in the diagnosis of malignancy, limiting their usefulness when indicating cytological studies by means of fine-needle aspiration (FNC). This situation motivated the development of risk stratification systems for thyroid nodules, which unified their ultrasound characteristics, with the aim of establishing risk categories, standardizing the preparation of reports, and providing the clinician with useful tools to define the surveillance option or form invasive studies.

The objective of this review is to compare the different systems developed by some scientific societies for the stratification of thyroid nodules, with respect to their predictive capacities for malignancy, their operational characteristics for diagnosis, and, to suggest recommendations for the implementation of these systems, placing emphasis on those with the best ability to reduce the performance of unnecessary invasive studies and to guide decision-making in the face of undetermined cytological results.

Introduction And Background

Thyroid nodules (TN) are common, found through palpation in 4%-7% and through thyroid ultrasound (US) in up to 70% of the population [1]. Actually, fine-needle aspiration biopsy (FNA) is the main tool to differentiate a benign from a malignant TN. Most TN (>90%) are not cancer; others are small and inert malignancies; therefore, FNA has to be restricted for those TN with clinical or radiological characteristics associated with thyroid carcinoma (TC) suspicion. Low-risk TN can undergo follow-up without any invasive procedure, avoiding complications and additional costs [1-4].

US suspicious findings are well-established, even though the report is operator-dependent [5]. Given the imaging findings, the clinician must establish which nodule to work up and which to follow up [5-6]. Hence, scientific societies recommend ultrasound risk stratification systems (RSS) to standardize reports and to make easier clinical decision-making [1-4] (to do or not FNA and further follow-up). The objective of this review is to compare the different RSS on their malignancy predictive value, diagnostic performance, and, additionally, to suggest recommendations to implement such systems, with an emphasis on those systems that may diminish the number of unnecessary invasive tests and guide in clinical decision-making when an undetermined cytologic result is observed. A narrative review was carried out using the Medline, Pubmed, Elsevier, Embase, and Google Scholar search engines, and the bibliographic documents published up to April 2020 were located. Words such as thyroid nodule, risk stratification systems, thyroid carcinoma, and thyroid ultrasound were used.

Review

Ultrasound risk stratification systems

Thyroid ultrasound is the first-line study to evaluate the risk of malignancy of a TN. It has been proven that some US characteristics increase the risk of malignancy, such as hypoechoic findings in the solid part of a nodule, taller-than-wide, irregular or spiculated margins with absent halo, microlcalcifications, and signs of extra-thyroidal growth. The malignancy risk associated with each characteristic is substantial, but none of these findings has a high enough diagnostic performance (sensitivity and specificity) to be used isolated one of the other [7]. Furthermore, these characteristics are subject to interpretation and affected by external factors such as the ultrasound equipment, the configuration and resolution of the screen, and the operator’s criteria. As a result, the interobserver and intraobserver concordance for each individual characteristic is moderate (Cohen’s Kappa coefficient: 0.4-0.6) [7].

Since 2005, multiple attempts have been done to diminish such limitations with US RSS [8]. These systems...
look to reduce the overdiagnosis and overtreatment of the current incidental TN "epidemic" [8]. RSS may differ one from the other. The US characteristics included in the RSS by the British Thyroid Association (BTA) [5], American Thyroid Association (ATA) [3], American Association of Clinical Endocrinologists (AACE), and Associazione Medici Endocrinologi (AME) [1] are shown in Table 1. These three systems categorize a TN based on the echographic pattern associated with a higher or lower risk of malignancy. Nonetheless, since the 2009 proposal of Horvath/Thyroid Imaging Reporting and Data System (TIRADS-Horvath) and further versions developed by the KWAK Thyroid Imaging Reporting and Data System (KWAK-TIRADS), Korean Thyroid Association (KTA)/Korean Society of Thyroid Radiology (KSThR), American College of Radiology-Thyroid Imaging Reporting and Data System (ACR-TIRADS), and the European Thyroid Association (ETA), a stratification score is used to determine the possibility of a TC [2,4-6,8].

| Ultrasound (US) characteristics | Horvath- TIRADS (2009) | Kwak- TIRADS (2009) | BTA (2014) | Revised ATA (2015) | AACE/ACE/ KTA (2016) | KSThR/ KTA (2016) | ACR- TIRADS (2017) | ETA (2017) |
|--------------------------------|------------------------|---------------------|-------------|-------------------|---------------------|-------------------|-------------------|--------------|
| **Benign US characteristics** |                        |                     |             |                   |                     |                   |                   |              |
| Cystic lesions                | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Spongiform/honeycomb pattern  | X                      | X                   | X           |                   |                     | X                 | X                 | X            |
| Mostly cystic nodules with liquid component and no suspicious signs associated | X                      | X                   | X           | X                 |                     | X                 | X                 | X            |
| Mostly cystic nodules with an eccentric solid pole     | X                      | X                   | X           |                   | X                   | X                 | X                 | X            |
| Isoechoic/hyperechoic nodule  | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Isoechoic/hyperechoic nodule with halo | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Oval shape                    |                        |                     |             |                   |                     |                   |                   |              |
| Comet tail artifact           |                        |                     |             |                   |                     | X                 | X                 | X            |
| Peripheral egg-shell like calcification | X                      |                     |             |                   |                     |                   |                   |              |
| Regular margins               | X                      | X                   | X           | X                 |                     | X                 | X                 |              |
| Absent vascularization        |                        |                     |             |                   |                     |                   |                   | X            |
| Peripheral vascularization    | X                      | X                   | X           |                   |                     |                   |                   |              |
| Regular halo                  | X                      |                     |             |                   |                     |                   |                   |              |
| **Malignant US characteristics** |                        |                     |             |                   |                     |                   |                   |              |
| Hypoechoic solid component    | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Markedly hypoechoic           | X                      | X                   |             |                   | X                   | X                 | X                 | X            |
| Irregular shape               | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Microcalcifications/punctate echogenic foci | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Calcifications Macrocacificaciones/globular calcifications | X                      | X                   | X           |                   | X                   | X                 |                   |              |
| Disrupted peripheral rim calcifications | X                      |                     |             |                   |                     |                   |                   | X            |
| Incomplete or broken peripheral calcification | X                      | X                   | X           |                   | X                   | X                 | X                 | X            |
| Hyperechoic spots of undetermined significance |                        |                     |             |                   |                     |                   |                   | X            |
| Irregular or spiculated margins with absent halo    | X                      | X                   | X           | X                 | X                   | X                 | X                 | X            |
| Intranodular vascularization  | X                      | X                   | X           | X                 | X                   | X                 |                   |              |
| Mixed vascularization (central and peripheral) |                        |                     |             |                   |                     |                   |                   |              |
| Invasion of thyroid parenchyma | X                      | X                   | X           |                   | X                   | X                 |                   | X            |
| Subcapsular or paratracheal lesions |                        |                     |             |                   |                     |                   |                   | X            |
| Pathologic adenopathy (hilum absence, microcalcifications, cystic degeneration, spherical shape, diffuse or peripheral | X                      | X                   | X           |                   |                     |                   |                   | X            |
hyper vascularization, hyperechoic aspect)

Central adenopathy with a minor axis >8 mm. Lateral adenopathy >10 mm

Metastasis

| TABLE 1: Benign and malignant US characteristics included in different RSS |
|---------------------------------------------------|
|Performed by the authors based on different cited guidelines in this review. |

TIRADS: Thyroid Imaging Reporting and Data System; BTA: British Thyroid Association; ATA: American Thyroid Association; AACE: American Association of Clinical Endocrinologists; ACE: American College of Endocrinology; AME: Associazione Medici Endocrinologi; KSThr: Korean Society of Thyroid Radiology; KTA: Korean Thyroid Association; ACR: American College of Radiology; ETA: European Thyroid Association

RSS has different categories, each with an estimated malignancy probability. These percentages were initially determined by expert consensus; the inter-system variability limits direct comparison as shown in Table 2. Some systems are derived from population data used in previous systems, without a proper validation study [9]. Regardless, in the last years, prospective validation in different cohorts has been performed.

| RSS | Category and estimated malignancy probability |
|-----|------------------------------------------------|
| ATA (2015) | Benign (<1%) | Very low-suspicion (<3%) | Low suspicion (5-10%) | Intermediate suspicion (10-20%) | High suspicion (70-90%) |
| BTA (2014) | U1-Normal (0%) | U2-Benign (<1%) | U3-Indeterminate (3-10%) | U4-Suspicious (10-20%) | U5- Malignant (70-90%) |
| AACE/ACE/AME (2016) | Low-risk (1%) | Intermediate-risk (5-15%) | High-risk (50-90%) |
| KSThr/KTA (2016) | K-TIRADS 1 (0%) | K-TIRADS 2 (0%) | K-TIRADS 3 (7.8%) | K-TIRADS 4 (25.4%) | K-TIRADS 5 (79.3%) |
| ACR TIRADS (2017) | TR1 - Benign (0%) | TR2 – Not suspicious (0%) | TR3 – Mildly suspicious (<5%) | TR4 - Moderately suspicious (5-80%) | TR4a: 5-10% TR4b: 10-50% TR4c: 50-80% | TR5 - Suspicious (>80%) |
| ETA (2017) | EU-TIRADS 1 Nodule (0%) | EU-TIRADS 2 Benign (0%) | EU-TIRADS 3 Low risk (2-4%) | EU-TIRADS 4 Intermediate risk (6-17%) | EU-TIRADS 5 High-risk (26-87%) |

| TABLE 2: Risk stratification systems and their categories. |
|----------------------------------------------------------|
|Performed by the authors based on different cited guidelines in this review. |

TIRADS: Thyroid Imaging Reporting and Data System; BTA: British Thyroid Association; ATA: American Thyroid Association; AACE: American Association of Clinical Endocrinologists; ACE: American College of Endocrinology; AME: Associazione Medici Endocrinologi; KSThr: Korean Society of Thyroid Radiology; KTA: Korean Thyroid Association; ACR: American College of Radiology; ETA: European Thyroid Association

Although these RSS are referenced in different guidelines, multiple difficulties may arise for daily use, whether it is for the technical conditions or physician work-load that may limit the duration of the US study. This may lead to sub-reports that do not meet the minimal characteristics, forcing them to perform another US evaluation to obtain the proper report.

**Diagnostic performance of risk stratification systems**

Given the rising use of RSS in clinical practice, multiple questions arise about its true diagnostic performance and the strengths and weaknesses of each system [8].

It is important to embrace guidelines to evaluate a diagnostic test from a critical perspective [10]. The first condition to evaluate a diagnostic test is the availability of a gold standard: the new test must offer at least the same diagnostic performance as the reference test. In the case of RSS, the underlying evidence has derived mainly from the population with papillary thyroid cancer (PTC). This introduces an important
selection bias because an FNA can adequately diagnose a PTC, but this isn’t the case for follicular carcinomas (FTCs) or medullary carcinomas (MTCs). FTC are indistinguishable from follicular adenomas and usually end up in an undetermined category [8].

MTC are misdiagnosed by FNA in up to 50% of cases [7]. However, there are multiple manuscripts that evaluated the diagnostic performance of RSS as compared to pathology reports of excisional biopsies (gold standard) of high/intermediate risk that underwent surgery, concluding a superior diagnostic performance than FNA. None of the RSS has a 100% capacity to determine the presence of TC. Nonetheless, RSS overall has a higher diagnostic performance and reproducibility than each of the individual risk characteristics [7-9].

In most RSS, an FNA indication is based on the TN US pattern and size. Each RSS establishes a different size limit to perform FNA in each risk category. Shen et al. retrospectively evaluated the US digital images of 1568 patients (1612 TN) that underwent surgery in a reference center. All the TN were histologically classified as benign or malignant. In Table 3, the diagnostic performance of four RSS is described according to the size of the TN in the study performed by Shen et al. [9]. Given the retrospective nature of the data, the validity of such findings may be compromised.

| Size    | RSS            | SEN (%) | SPE (%) | PPV (%) | NPV (%) | AUC (%)          |
|---------|----------------|---------|---------|---------|---------|------------------|
| < 10 mm | ATA ACR ETA K-TIRADS | 96.4 95.3 | 85.1 66.6 | 167.8 56.2 | 85.2 | 87.9 86.1 91.9 78.6 (74.0-83.3) 81.1 (76.7-85.6) 79.4 (74.7-84.0) 80.8 (76.3-85.4) |
| >10 y < 20 mm | ATA ACR ETA K-TIRADS | 86.8 81.9 | 81.5 88.0 | 80.4 | 77.4 83.7 76.6 | 82.4 | 89.4 87.0 90.1 | 84.4 (81.0-87.9) 85.1 (81.6-88.6) 84.2 (80.6-88.6) 87.3 (84.1-90.5) |
| > 20 mm | ATA ACR ETA K-TIRADS | 88.0 79.7 | 93.0 97.6 | 91.8 | 83.6 93 81.8 | 91 | 91.5 92.4 97.4 | 91.0 90.5 (86.9-94.2) 88.6 (84.6-93.3) 91.4 (88.1-94.9) 93.9 (91.1-97.2) |

TABLE 3: Diagnostic performance of four RSS for TN of different sizes.

RSS: risk stratification system; SEN: sensitivity; SPE: specificity; PPV: positive predictive value; NPV: negative predictive value; AUC: area under the curve; ATA: American Thyroid Association; ACR: American College of Radiology; ETA: European Thyroid Association; K-TIRADS: KWAK-Thyroid Imaging Reporting and Data System

Performed by the authors based on different cited guidelines in this review.

Zhang et al. prospectively categorized 3980 TN (3752 benign lesions and 228 malignant) between October 2011 and June 2013 in 2921 outpatients in Shanghai, China, using the KWAK-TIRADS system. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and precision were 97%, 90%, 40%, 99%, and 91%, respectively [11]. K-TIRADS has been validated by a prospective, multicentric study of four institutions with 902 TN. Sensitivity, specificity, PPV, NPV and precision for malignant TN were 95.5%, 58.6%, 44.5%, 96.9% and 69.5%, respectively [12]. The prospective validation of EU-TIRADS showed a 86.1% sensitivity, 32% specificity, 8.9% PPV, and 96.7% NPV [13].

These data were extracted from individual prospective validation studies; unfortunately, these results are not enough to establish the best system [11-13].

Recently, in a prospective study with 987 TN sent for FNA, the diagnostic accuracy for the malignancy of the RSS proposed by BTA, ATA, and AACE/ACE/AME was evaluated, comparing the high risk to the low/intermediate-risk categories and high/intermediate-risk to low-risk categories (Table 4) [14]. The conclusion is that the three systems have a similar diagnostic performance. The reported negative predictive value (NPV) is equal or higher to 95%, a useful aspect to evaluate TN, especially those in the low-risk category, as those TN have a low pre-test probability for malignancy, follow-up can be performed by US alone [14].
TABLE 4: Diagnostic performance for the malignancy of the BTA, ATA, and AACE/ACE/AME risk stratification systems, comparing low and intermediate risk vs high risk

| RSS | BTA | ATA | AACE/ACE/AME |
|-----|-----|-----|--------------|
| Risk category | U2 and U3 vs U4 and U5 | 1,2,3 and 4 vs 5 | 1 and 2 vs 3 |
| SEN | 74% | 81% | 82% |
| SPE | 92% | 87% | 87% |
| PPV | 62% | 54% | 54% |
| NPV | 95% | 96% | 96% |
| Precision | 89% | 86% | 86% |
| Risk category | U2 vs U3, U4, and U5 | 1 and 2 vs 3, 4, and 5 | 1 vs 2 and 3 |
| SEN | 90% | 98% | 99% |
| SPE | 63% | 21% | 21% |
| PPV | 32% | 19% | 19% |
| NPV | 97% | 98% | 99% |
| Precision | 68% | 33% | 34% |

Despite the researchers’ efforts, no RSS has been widely embraced, and there are some contradicting recommendations between different institutions [8,14].

Strategies to reduce unnecessary thyroid biopsies

The target of the TIRADS system is to improve clinical decision-making and to reduce unnecessary FNA (7). The rate of unnecessary FNA to diagnose TC was defined as the percentage of benign TN divided by the total number of patients that underwent FNA. Xu et al. observed an unnecessary FNA rate of 25.2%, based on EU-TI-RADS [15].

Recently, Castellana et al. included 12 studies in a meta-analysis with 18750 TN. The population included was outpatient adults with TN that underwent FNA, core needle biopsy, or surgery that had US images available. The final diagnosis of malignant nodules was based on histology; cytology was used for diagnosis in benign nodules. The diagnostic odds ratio (DOR) was 2.2-4.9. A head-to-head comparison to select TN that should undergo FNA observed a higher DOR for ACR-TI-RADS against ATA (p = 0.002) or K-TI-RADS (p = 0.002); hence, ACR-TI-RADS yielded a higher diagnostic performance to select patients that had to undergo an invasive procedure. Nonetheless, these results must be confirmed in further studies [16].

In another study by Grani et al., 902 TN were evaluated, and the rate of unnecessary FNA was lower with ACR-TIRADS (25.8%), followed by ATA (51.2%), and K-TI-RADS (59.4%) [6]. The ACR-TI-RADS system was superior to the other systems, identifying more than 50% of biopsies as unnecessary, and with a lower false negatives rate. This difference is due to the size threshold for FNA in each RSS, as shown in Table 5 [6].
Size threshold for FNA indication in each system

| RSS          | AACE/ACE/AME (2016) | TR5 FNA > 10 mm | ATA (2015) | TR4 FNA > 15 mm | KSThR/ KTA (2016) | TR3 FNA > 15 mm | ETA (2017) | TR2 No FNA |
|--------------|---------------------|-----------------|------------|-----------------|-------------------|-----------------|------------|------------|
| High-risk    | 2016                | 2017            | 2015       | 2016            | 2017              | 2017            | 2017       | 2017       |
| FNA > 10 mm  | TR5 FNA > 10 mm     | High-risk FNA > 10 mm | TR4 FNA > 10 mm | TR4 FNA > 15 mm | TR3 FNA > 10 mm | TR3 FNA > 15 mm | TR2 No FNA |
| Intermediate-|                    |                 |            |                 |                   |                 |            |            |
| FNA > 20 mm  | TR4 FNA > 15 mm     | Intermediate-risk FNA > 10 mm | TR4 FNA > 10 mm | TR4 FNA > 15 mm | TR3 FNA > 15 mm | TR3 FNA > 20 mm | TR2 No FNA |
| Low-risk     | TR2 No FNA          | Very-low-risk FNA > 20 mm | TR2 FNA > 20 mm | TR2 No FNA |                   |                 |            |            |
| FNA > 20 mm  | TR1 No FNA          | Benign no FNA   | -          | -               |                   |                 |            |            |

TABLE 5: Size threshold for FNA indication in five different RSS

FNA: Fine-needle aspiration biopsy; TIRADS: Thyroid Imaging Reporting and Data System; ATA: American Thyroid Association; AACE: American Association of Clinical Endocrinologists; ACE: American College of Endocrinology; AME: Associazione Medici Endocrinologi; KSTH: Korean Society of Thyroid Radiology; KTA: Korean Thyroid Association; ACR: American College of Radiology; ETA: European Thyroid Association

In conclusion, to reduce the number of unnecessary biopsies, FNA is recommended for TN of intermediate risk (TIRADS category 3) with a size > 25 mm, and TIRADS category 4 with a size > 15 mm [2,17].

The role of clinical examination, ultrasound, and new biopsy in the follow-up of benign TN is unclear. In most cases, clinical examination, ultrasound, and thyroid-stimulating hormone are performed at six to 18 months in patients in whom biopsy is not indicated. A new FNA can be considered if a TN increases in size, defined as an increase of at least 20% in two dimensions (minimum 2 mm), if cystic degeneration is observed, or in case of suspect clinical or ultrasound changes [2-4].

Can risk stratification systems rule out malignancy in cytologically undetermined thyroid nodules?

The Bethesda system for reporting thyroid cytopathology classifies FNA cytology into six categories [17]. For both benign and malignant TN, further management is quite clear [1-5]. However, undetermined results can portray a challenge for clinical decision-making: to repeat or not to repeat FNA, perform thyroid surgery, or follow-up. This challenge is due to most TN with undetermined FNA results (atypia of undetermined significance AUS/ follicular lesion of undetermined significance (FLUS), Follicular neoplasm, and suspicious for malignancy) are histologically benign, with a malignancy risk of 10-30% for Bethesda III (B-III) and 25%-40% for B-IV [18].

The malignancy uncertainty of undetermined samples leads to uncertain treatment selection [5,18]. Some studies reported that a repeat FNA might obtain a definitive diagnosis in the B-III category; however, 10%-30% nodules keep the same undetermined results, hence making a case against repeat FNA [17]. In those cases where two FNAs had undetermined results and surgery was performed with benign surgical pathology results, the definitive pathology result suggested that the surgical approach was unnecessary [9,19]. These cases may benefit from molecular tests to improve diagnostic precision. However, molecular tests are expensive, which can lead to diagnostic delays and routine clinical use limitations [1-4].

In the last few years, alternative, less invasive approaches have been proposed to reduce unnecessary interventions, costs, and complications [18,20].

When a TN has a B-III cytology, with a TIRADS 2, 3, and 4a US report (estimated malignancy risk of 0–10%), a repeat FNA at six to 12 weeks may cause “changes due to external factors,” leading to degenerative processes in the TN through a hemorrhage, granulation tissue, fibrosis, and sclerosis [5,9,20]. These changes can be observed as spontaneous degenerative TN changes, called “changes due to internal factors,” which can lead to confusion in cytological evaluation [21-22].

In subjects with undetermined cytology (especially in the B-III and B-IV categories), a correlation between RSS with cytological category has been proposed, to further define on whom to perform follow-up, molecular tests, or surgery. In a retrospective study with 140 definitive pathology, US, and FNA results, a correlation between low-risk US categories (according to ATA and ACR-TIRADS) and low risk for malignancy in cases with a B-III cytology [23]. Barbosa et al. reported that in cases with B-III cytology that also had a TIRADS...
category 2, 3, and/or 4, or a very low-risk/low risk/intermediate ATA category, the NPV to rule out malignancy was 94.1% and 94.3%, respectively, favoring a conservative approach in this scenario. Nonetheless, in cases with B-III cytology and higher US risk categories (TI-RADS 4b, 4c, and 5; high-risk ATA), the NPV was 68 and 45.5%. The malignancy risk is higher in these cases, and it isn’t possible to rule out malignancy with US alone [23].

A pragmatic approach to undetermined TN, published in 2017, proposed the following clinical decision-making: in TN with a B-III result, the US must be re-visited. If high-risk characteristics are observed (TI-RADS: 4b, 4c, and 5), the surgical approach is recommended [23]. In TN with a B-IV result, RSS utility is limited to rule out malignancy and must not be used in this scenario for clinical decision-making. If there are no molecular tests available, surgery can be considered [24].

Conclusions
Ultrasound RSS are tools that must be used in the TN workup. These systems have more similarities than differences. The clinical decision-making suggestions in this review are done to reduce unnecessary invasive procedures and complications and decrease associated healthcare costs. Among the results of prospective studies and a recent meta-analysis, ACR-TIRADS has shown higher diagnostic performance as compared to ATA, BTA, EU-TIRADS, and K-TIRADS; it has also shown better classification to either perform FNA or continue follow-up in low-risk TN.

For the development of this narrative review, the clinical practice guidelines published by the different international scientific societies were included in addition to the original research works that evaluate the usefulness and performance of RSS. A limitation evidenced in these publications was the retrospective nature of an important number of studies, so we gave priority to those with a prospective methodological design to reduce the possibility of bias. The data described is consistent and allows us to conclude that the use of a validated RSS, such as ACR-TIRADS, must be embraced, to standardize the same language, and to design to reduce the possibility of bias. The data described is consistent and allows us to conclude that the use of a validated RSS, such as ACR-TIRADS, must be embraced, to standardize the same language, and to design to reduce the possibility of bias.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Ghazib H, Papini E, Garber JR, et al.: American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016, 22:622-639. 10.4158/EP161208.GL.
2. Tessler FN, Middleton WD, Grant EG, et al.: ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017, 14:587-595. 10.1016/j.acra.2017.01.046
3. Haugen BR, Alexander EK, Bible KC, et al.: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016, 26:1-133. 10.1089/thy.2015.0020
4. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L: European Thyroid Association Guidelines for ultrasound malignancy risk stratification of thyroid nodules in Adults: the EU-TIRADS. Eur Thyroid J. 2017, 6:225-237. 10.1159/000478927
5. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS: The diagnosis and management of thyroid nodules a review. JAMA. 2018, 319:919-924. 10.1001/jama.2018.0898
6. Grani G, Lamartina L, Ascoli V, et al.: Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: toward the “right” TIRADS. J Clin Endocrinol Metab. 2019, 104:95-102. 10.1210/jc.2018-01674
7. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, Durante C: Interobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect. 2018, 7:1-7. 10.1530/EC-17-0536
8. Trimborli P, Durante C: Ultrasound risk stratification systems for thyroid nodule: between lights and shadows, we are moving towards a new era. Endocrine. 2020, 69:1-4. 10.1007/s12020-020-02196-6
9. Shen Y, Liu M, He J, et al.: Comparison of different risk-stratification systems for the diagnosis of benign and malignant thyroid nodules. Front Endocrinol. 2019, 9:578. 10.3389/fendo.2019.00578
10. Ruiz A, Cuervo L: Pruebas diagnosticas. Generalidades de su interpretación [Article in Spanish]. Rev Col Neumol. 2008, 20:98-105.
11. Zhang J, Liu B-J, Xu H-X, et al.: Prospective validation of an ultrasound-based thyroid imaging reporting and data system (TI-RADS) on 5980 thyroid nodules. Int J Clin Exp Med. 2015, 8:5911-5917.
12. Ha EJ, Moon W-J, Na DG, Lee YH, Choi N, Kim SJ, Kyun Kim IK: A multicenter prospective validation study
for the Korean thyroid imaging reporting and data system in patients with thyroid nodules. Korean J Radiol. 2016, 1:811-821. 10.5354/kjr.2016.17.5.811

13. Maino F, Forleo R, Martinelli M, et al.: Prospective validation of ATA and ETA sonographic pattern risk of thyroid nodules selected for FNAC. J Clin Endocrinol Metab. 2018, 1:2362-2368. 10.1210/jc.2018-00274

14. Persichetti A, Di Stasio E, Guglielmi R, et al.: Predictive value of malignancy of thyroid nodule ultrasound classification systems: a prospective study. J Clin Endocrinol Metab. 2018, 105:1359-1368. 10.1210/jc.2017-01708

15. Floridi C, Cellina M, Buccimazza G, et al.: Ultrasound imaging classifications of thyroid nodules for malignancy risk stratification and clinical management: state of the art. Gland Surg. 2019, 1:233-244. 10.21037/gs.2019.07.01

16. Castellana M, Castellana C, Treglia G, Giorgino F, Giovanella L, Russ G, Trimbol P: Performance of five ultrasound risk stratification systems in selecting thyroid nodules for FNA. J Clin Endocrinol Metab. 2020, 105:1659-1669. 10.1210/cclinem/dgz170

17. Baloch ZW, LiVolsi VA, Asa SL, et al.: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the national cancer institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol. 2008, 36:425-437. 10.1002/dc.20830

18. Ahmed S, Herbst R, Oyekunle T, et al.: Using the ATA and ACR TI-RADS sonographic classifications as adjunctive predictors of malignancy for indeterminate thyroid nodules. Endocr Pract. 2019, 1:908-917. 10.4158/EP-2018-0559

19. Yip L: Molecular diagnostic testing and the indeterminate thyroid nodule. Curr Opin Oncol. 2014, 26:8-13. 10.1097/CCO.000000000000023

20. Grani G, Lamartina L, Ascoli V, et al.: Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. Endocrine. 2017, 57:256-261. 10.1007/s12020-016-1148-6

21. Erkan M, Canberk S, Kilicoglu GZ, Osenek M, Uludokumaci A, Gunes P, Atanoy T: Avoidance of unnecessary fine-needle aspiration with the use of the Thyroid Imaging Reporting Data System classification and strain elastography based on The Bethesda System for Reporting Thyroid Cytopathology. Mol Clin Oncol. 2016, 5:625-630. 10.3892/mco.2016.1003

22. Cibas ES, Ali SZ: The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017, 27:1341-1346. 10.1089/thy.2017.0550

23. Madsen Barbosa TL, Mesa CA Junior, Graf H, et al.: ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology. BMC Endocr Disord. 2019, 19:112. 10.1186/s12902-019-0429-5

24. Seshadri K: A pragmatic approach to the indeterminate thyroid nodule. Indian J Endocrinol Metab. 2017, 21:751-757.